Firmicutes

The bacteria living inside your intestines are roughly as numerous as your own cells (older estimates of a 10-to-1 ratio have been revised to about 1-to-1), and one large group of them, Firmicutes, makes up much of that community. A stool test that quantifies Firmicutes gives you a snapshot of how much of your gut bacterial community belongs to this group, which has been studied in obesity, diabetes, inflammatory bowel disease, depression, Parkinson's disease, and more.

This is a research-grade measurement, not an established clinical lab. Firmicutes levels shift with age, sex, diet, and disease, but no single number applies to everyone, and the direction of change is not the same across conditions. The value comes from seeing where you currently sit and watching how your number moves over time, not from comparing it to a fixed threshold.

What This Test Actually Measures

Firmicutes is not a hormone, protein, or enzyme your body produces. It is a category of bacteria, and the test measures bacterial DNA in your stool. Laboratories use different approaches: some run quantitative PCR (polymerase chain reaction) to amplify and count specific bacterial sequences directly, while broader microbiome profiling typically uses 16S rRNA amplicon sequencing or shotgun metagenomics, which read many bacterial sequences at once. Most labs then report Firmicutes as a percentage of all bacterial DNA in the sample, often paired with Bacteroidetes, the other dominant gut group.

Firmicutes includes hundreds of different species. Some, like Faecalibacterium and Roseburia, produce butyrate, a short-chain fatty acid that helps calm gut inflammation and feed the cells lining your colon. Others extract more calories from food or track with inflammation. This means two people with the same Firmicutes percentage can have very different gut ecosystems doing very different things inside them.

Body Weight and Metabolism

Findings here go in both directions. In a study of 79 Egyptian children and adults, Firmicutes were more abundant in obese participants than in normal-weight ones. A study of 51 children in Trinidad also found significantly more Firmicutes in children with overweight or obesity, with a positive link between Firmicutes abundance and BMI. But in a study of 98 adults, the Firmicutes-to-Bacteroidetes ratio actually shifted toward Bacteroidetes in overweight and obese subjects. A large review of pooled human data concluded that healthy people show Firmicutes anywhere from 11% to 95% of their gut community, and the variation between individuals dwarfs any consistent obesity signal.

Reconciling the Mixed Findings

The apparent contradiction has a clean explanation. Firmicutes is a category, not a single bug. The phylum holds species that produce anti-inflammatory short-chain fatty acids and species that do not, so a Firmicutes count alone cannot tell you whether the helpful or unhelpful members are winning. This is why Firmicutes works better as a research signal you track over time than as a 'good number, bad number' marker.

Type 1 and Type 2 Diabetes

In a study of 106 adults in Turkey with type 1 diabetes, Firmicutes were significantly lower and the Firmicutes-to-Bacteroidetes ratio was reduced compared with healthy controls. In type 2 diabetes, a study of 56 adults found that Firmicutes proportions were significantly lower in diabetic participants, and the Bacteroidetes-to-Firmicutes ratio correlated with blood sugar levels. A separate study of 100 adults with type 2 diabetes pointed the opposite way, with higher Firmicutes in diabetics. The species inside the phylum likely matter more than the phylum total.

Inflammatory Bowel Disease

Stool research on inflammatory bowel disease (IBD) is split. Earlier work found Firmicutes less represented and the Firmicutes-to-Bacteroidetes ratio lower in active IBD compared with healthy participants, with markedly reduced Faecalibacterium prausnitzii. In a more recent case-control study of 60 adults, Firmicutes were significantly higher in both Crohn's disease and ulcerative colitis compared with controls. Across both lines of research, the butyrate-producing species Faecalibacterium prausnitzii was consistently reduced in IBD, supporting the idea that the specific species inside Firmicutes carry more clinical meaning than the phylum total.

Parkinson's Disease, Depression, and Alzheimer's

In a study of 65 people with Parkinson's disease, Firmicutes and the Firmicutes-to-Bacteroidetes ratio were significantly decreased compared with controls. In multiple cohorts of people with major depressive disorder, Firmicutes were significantly reduced compared with healthy participants. In 172 people with Alzheimer's disease, Firmicutes and Bacteroidetes abundance fell as disease progressed. These are associations rather than causal links, but they show that gut bacterial composition tracks with brain-related conditions.

Liver Disease and Cancer

In a study of 37 people with nonalcoholic fatty liver disease, the Firmicutes-to-Bacteroidetes ratio correlated with the amount of fat in the liver and with central obesity. In colorectal cancer, the picture inside Firmicutes is mixed: one Iranian study reported certain Firmicutes genera, including Eubacterium and Faecalibacterium, were increased in patient stool samples, but most meta-analyses and larger pooled datasets find Faecalibacterium prausnitzii is actually decreased in colorectal cancer, so this is one of the situations where a single study disagrees with the broader literature. In cirrhotic patients with hepatocellular carcinoma, family-level shifts within Firmicutes were detected, including a 3-fold rise in Erysipelotrichaceae compared with cirrhotic patients without cancer.

Age and Sex

In a study of 1,550 healthy Ukrainians, Firmicutes abundance rose and Bacteroidetes fell from childhood into adulthood, then shifted again in older age. One published comparison reported Firmicutes-to-Bacteroidetes ratios of about 0.4 in infants, 10.9 in adults, and 0.6 in the elderly. In a separate analysis of 2,201 Ukrainians, women had higher Firmicutes and a higher Firmicutes-to-Bacteroidetes ratio than men. Any single result needs to be read against what is typical for someone of your age and sex.

Tracking Your Trend

A single Firmicutes reading is not a diagnosis. Healthy people show wide differences, with Firmicutes ranging from 11% to 95% of the gut microbiome across studies. Lab methodology, including DNA extraction, primer choice, sequencing region, and software pipeline, can shift the measured number, so results from different labs are not directly comparable. The useful information comes from watching how your own number changes after meaningful interventions, like a major diet shift, a course of antibiotics, or treatment for a gut condition.

Get a baseline now, retest in 3 to 6 months if you are actively changing your diet or treating a gut issue, and then track at least annually. The trend in your own gut, measured by the same lab using the same method, is more informative than any comparison to a published 'normal' range.

When Results Can Be Misleading

• Recent antibiotics: a course of antibiotics can substantially reshape your gut community for weeks to months (and for some antibiotic classes, residual effects have been documented for years), and a Firmicutes reading taken in that window may not reflect your usual state.
• Lab methodology: the choice of DNA extraction, primer set, sequencing pipeline, and whether the lab uses targeted qPCR or broader 16S/shotgun sequencing can change the measured Firmicutes percentage. Stick with one lab to make your own results comparable over time.
• Storage and handling: standard refrigeration looks acceptable, but storage with certain preservative buffers can alter microbiome readouts, so follow the lab's collection instructions exactly.
• Recent diet shifts and travel: a recent dramatic change in fiber, fat, or animal protein intake, or travel to a new geographic area, can move the number short-term. Try to test under typical conditions for you.

What to Do With an Unusual Result

An out-of-pattern Firmicutes result is a starting point, not a verdict. Pair it with a broader stool microbiome panel that breaks the phylum down into species, especially Faecalibacterium prausnitzii, Roseburia, and Akkermansia muciniphila, since these species carry more interpretive weight than the Firmicutes total. If you also have digestive symptoms, consider stool markers of inflammation and digestion, such as calprotectin and pancreatic elastase, and discuss the combined picture with a gastroenterologist. If your result is unexpected and you have no symptoms, the most useful next step is usually to retest in a few months under steady conditions to see whether the finding is real or simply day-to-day noise.